12/20
11:27 am
atos
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Medium
Report
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
12/12
12:37 pm
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright.
Low
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright.
12/12
08:15 am
atos
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
Medium
Report
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
12/11
08:15 am
atos
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
Medium
Report
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
12/10
09:22 am
atos
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium [Yahoo! Finance]
Low
Report
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium [Yahoo! Finance]
12/10
09:05 am
atos
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
Neutral
Report
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
12/9
08:15 am
atos
Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research
Low
Report
Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research
12/9
08:11 am
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $6.50 to $7.00. They now have a "buy" rating on the stock.
Low
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $6.50 to $7.00. They now have a "buy" rating on the stock.
11/21
08:38 am
atos
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research [Yahoo! Finance]
Neutral
Report
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research [Yahoo! Finance]
11/21
08:30 am
atos
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research
Low
Report
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research
11/20
08:30 am
atos
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium
Medium
Report
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium
11/19
12:09 am
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/13
01:45 pm
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its price target raised by analysts at HC Wainwright from $6.00 to $7.00. They now have a "buy" rating on the stock.
Medium
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its price target raised by analysts at HC Wainwright from $6.00 to $7.00. They now have a "buy" rating on the stock.
11/12
08:30 am
atos
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
11/8
11:07 pm
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/5
08:44 am
atos
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development [Yahoo! Finance]
Low
Report
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development [Yahoo! Finance]
11/5
08:30 am
atos
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development
Low
Report
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development
11/4
06:30 am
atos
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:
Medium
Report
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:
10/31
10:42 am
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
10/31
08:15 am
atos
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer
Low
Report
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer
10/28
11:40 am
atos
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? [Yahoo! Finance]
Low
Report
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? [Yahoo! Finance]
10/25
11:05 pm
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
10/21
08:30 am
atos
Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer
Low
Report
Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer
10/14
05:15 pm
atos
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit [Yahoo! Finance]
Low
Report
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit [Yahoo! Finance]
10/14
05:08 pm
atos
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit
Low
Report
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit